Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07314216
What this trial is testing

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)Stage IIIEGFR Uncommon Mutations
Hunan Cancer Hospital 15
Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT07362940
What this trial is testing

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Who this might be right for
Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd. 110
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Large-scale testing (Phase 3)UnknownNCT02125240
What this trial is testing

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 124
Testing effectiveness (Phase 2)Ended earlyNCT02454842
What this trial is testing

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Rain Oncology Inc 21
Not applicableUnknownNCT03764917
What this trial is testing

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableUnknownNCT01359436
What this trial is testing

E- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 200
Testing effectiveness (Phase 2)Ended earlyNCT03292133
What this trial is testing

EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 11
Large-scale testing (Phase 3)UnknownNCT04874844
What this trial is testing

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Who this might be right for
NSCLC
Beijing Dongfang Biotech Co., Ltd. 420
Testing effectiveness (Phase 2)Study completedNCT04965090
What this trial is testing

Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Metastatic Non Small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 43
Testing effectiveness (Phase 2)UnknownNCT05534113
What this trial is testing

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06300424
What this trial is testing

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Guangdong Provincial People's Hospital 32
Early research (Phase 1)Study completedNCT01967095
What this trial is testing

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Who this might be right for
EGFR-Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Testing effectiveness (Phase 2)Looking for participantsNCT07699328
What this trial is testing

VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc 315
Large-scale testing (Phase 3)Ended earlyNCT05493501
What this trial is testing

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
EQRx International, Inc. 8
Early research (Phase 1)Not Yet RecruitingNCT06067776
What this trial is testing

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Jonathan Riess 36
Testing effectiveness (Phase 2)UnknownNCT05946460
What this trial is testing

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Who this might be right for
Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 22
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Next Page